Welcome to LookChem.com Sign In|Join Free


  • or


Post Buying Request

143782-23-4 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

143782-23-4 Usage


Different sources of media describe the Uses of 143782-23-4 differently. You can refer to the following data:
1. 4-Isothiocyanoyl-2-(trifluoromethyl)benzonitrile is a reagent used to synthesize thioimidazolinone compounds and is a potential anti-prostate cancer drug. It is also used as an intermediate of enzalutamide.
2. 4-Cyano-3-trifluoromethylphenylisothiocyanate is an reagent used in the synthesis of thioxoimidazolidinones as potential anti-prostate cancer agents.


4-Amino-2-trifluoromethylbenzonitrile, (2.23 g, 12 mmol) was added portionwise over15 minutes into the well-stirred heterogeneous mixture of thiophosgene (1 ml, 13 mmol) in water (22 ml) at room temperature. Stirring was continued for an additional 1 h. The reaction medium was extracted with chloroform (3 x 15 ml). The combined organic phase was dried over MgSO4 and evaporated to dryness under reduced pressure to yield desired product, 4-isothiocyanato-2-trifluoromethylbenzonitrile, (Ia), as brownish solid and was used as such for the next step (2.72 g, 11.9 mmol, 99%).

Check Digit Verification of cas no

The CAS Registry Mumber 143782-23-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,4,3,7,8 and 2 respectively; the second part has 2 digits, 2 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 143782-23:
134 % 10 = 4
So 143782-23-4 is a valid CAS Registry Number.



According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 10, 2017

Revision Date: Aug 10, 2017


1.1 GHS Product identifier

Product name 4-Isothiocyanato-2-(trifluoromethyl)benzonitrile

1.2 Other means of identification

Product number -
Other names Isothiocyanic Acid 4-Cyano-3-(trifluoromethyl)phenyl Ester

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:143782-23-4 SDS

143782-23-4Relevant articles and documents

Spirocyclic Thiohydantoin Antagonists of F877L and Wild-Type Androgen Receptor for Castration-Resistant Prostate Cancer

Zhang, Zhuming,Connolly, Peter J.,Trabalón Escolar, Luis,Rocaboy, Christian,Pande, Vineet,Meerpoel, Lieven,Lim, Heng-Keang,Branch, Jonathan R.,Ondrus, Janine,Hickson, Ian,Bush, Tammy L.,Bischoff, James R.,Bignan, Gilles

, p. 1245 - 1252 (2021)

Androgen receptor (AR) transcriptional reactivation plays a key role in the development and progression of lethal castration-resistant prostate cancer (CRPC). Recurrent alterations in the AR enable persistent AR pathway signaling and drive resistance to the treatment of second-generation antiandrogens. AR F877L, a point mutation in the ligand binding domain of the AR, was identified in patients who acquired resistance to enzalutamide or apalutamide. In parallel to our previous structure-activity relationship (SAR) studies of compound 4 (JNJ-pan-AR) and clinical stage compound 5 (JNJ-63576253), we discovered additional AR antagonists that provide opportunities for future development. Here we report a highly potent series of spirocyclic thiohydantoins as AR antagonists for the treatment of the F877L mutant and wild-type CRPC.

Exploring the tetrahydroisoquinoline thiohydantoin scaffold blockade the androgen receptor as potent anti-prostate cancer agents

Xu, Xi,Ge, Raoling,Li, Lei,Wang, Jubo,Lu, Xiaoyu,Xue, Siqi,Chen, Xijing,Li, Zhiyu,Bian, Jinlei

, p. 1325 - 1344 (2018)

Prostate cancer (PC) is a major cause of cancer-related male death in worldwide and the identification of new and improved potent anti-PC molecules is constantly required. A novel scaffold of tetrahydroisoquinoline thiohydantoin was rationally designed based on the enzalutamide structures and our pre-work, leading to the discovery of a series of new antiproliferative compounds. Several new analogues displayed improved androgen receptor (AR) antagonistic activity, while maintaining the higher selective toxicity toward LNCaP cells (AR-rich) versus DU145 cells (AR-deficient) compared to enzalutamide. In fact, compound 55 exhibited promising in vitro antitumor activity by impairing AR unclear translocation. More importantly, 55 showed better pharmacokinetic properties compared to the compound 1 reported in our pre-work. These results demonstrate a step towards the development of novel and improved AR antagonists.

Synthesis method of 4-isothiocyanato-2-(trifluoromethyl)benzonitrile


Paragraph 0012; 0026; 0029-0030-0031; 0034-0035, (2021/06/02)

The invention discloses a synthesis method of 4-isothiocyanato-2-(trifluoromethyl)benzonitrile. The synthesis method comprises the following steps: with 3-trifluoromethyl-4-cyanobenzoic acid as an initial raw material, firstly, subjecting 3-trifluoromethyl-4-cyanobenzoic acid to reacting with diphenyl azidophosphate under an anhydrous condition to generate 4-isocyanato-2-(trifluoromethyl)benzonitrile, and then subjecting 4-isocyanato-2-(trifluoromethyl)benzonitrile to reacting with a Lawson reagent to obtain the compound 4-isothiocyanato-2-(trifluoromethyl)benzonitrile. The method has the advantages of simple synthetic route, one-pot reaction, mild reaction conditions, simple post-treatment, high product yield (wherein total yield is greater than or equal to 83.9%), and easy industrial production.

Design, synthesis and biological evaluation of novel thiohydantoin derivatives as potent androgen receptor antagonists for the treatment of prostate cancer

Wang, Ao,Wang, Yawan,Meng, Xin,Yang, Yushe

, (2021/01/07)

Prostate cancer (PC) is the most common malignancy in men worldwide. Here, two series of novel thiohydantoin derivatives of enzalutamide as potent androgen receptor (AR) antagonists were designed and synthesized. Among them, compound 31c was identified as an AR antagonist which is 2.3–fold more potent than enzalutamide. Molecular docking studies were performed to explain the improved potency of 31c at AR. In cell proliferation assays, 31c exhibited similar anti-proliferative activities with enzalutamide against hormone sensitive LNCaP cells and AR-overexpressing LNCaP/AR cells. These data indicate that 31c can be a good lead compound for further structure optimization for the treatment of prostate cancer.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)


What can I do for you?
Get Best Price

Get Best Price for 143782-23-4